Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

385
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
385
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

234
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
234
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

181
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
181
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

122
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
122
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

205
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
205

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatocellular Carcinoma Around the Clock.

Current oncology (Toronto, Ont.)·2026
Same author

The Beauty Sleep to Keep a Healthy Liver.

International journal of molecular sciences·2025
Same author

Meta-Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis.

Alimentary pharmacology & therapeutics·2025
Same author

Circadian Deregulation: Back Facing the Sun Toward Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development.

Nutrients·2025
Same author

The Changing Face of Hepatitis Delta Virus Associated Hepatocellular Carcinoma.

Cancers·2024
Same author

Refractory Celiac Disease: What the Gastroenterologist Should Know.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Aug 13, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K

New Developments in Celiac Disease Treatment.

Mariana Verdelho Machado1,2

  • 1Gastroenterology Department, Hospital de Vila Franca de Xira, Estrada Carlos Lima Costa, Nª 2, 2600-009 Vila Franca de Xira, Portugal.

International Journal of Molecular Sciences
|January 21, 2023
PubMed
Summary

Celiac disease (CD) management is challenging due to strict gluten-free diets (GFD) and frequent dietary contamination. This review explores promising pharmacological treatments to improve quality of life for CD patients.

Keywords:
celiac diseasegluten-free dietpharmacological treatments

More Related Videos

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.8K
Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.0K

Related Experiment Videos

Last Updated: Aug 13, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.8K
Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

15.0K

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Celiac disease (CD) is an autoimmune disorder affecting 1% of the population, triggered by gluten in susceptible individuals.
  • A lifelong gluten-free diet (GFD) is the only current treatment, but adherence is difficult, leading to persistent symptoms and poor recovery.
  • Gluten contamination affects a majority of patients on GFD, highlighting the need for alternative therapies.

Purpose of the Study:

  • To review the current rationale behind developing pharmacological treatments for celiac disease.
  • To summarize the main clinical trials investigating drug therapies for CD.

Main Methods:

  • Literature review of recent research and clinical trials on celiac disease drug therapy.
  • Analysis of the current therapeutic landscape and future directions for CD management.

Main Results:

  • Despite GFD adherence, significant gluten exposure and persistent symptoms remain common in celiac disease patients.
  • Ongoing research focuses on novel pharmacological approaches to complement or replace the GFD.
  • Several drug therapies are in clinical trials, targeting different aspects of the disease pathophysiology.

Conclusions:

  • Pharmacological treatments hold promise for improving outcomes and quality of life for celiac disease patients.
  • Further research and clinical trials are essential to establish effective and safe drug therapies for CD.
  • The development of drug therapies could significantly alleviate the burden of celiac disease management.